Alchemab and Lilly Partner, Alchemab to Oversee Phase I Trials of ATLX-1282 for ALS

Alchemab Therapeutics and Eli Lilly and Company have entered into an agreement regarding the development of ATLX-1282 for the treatment of amyotrophic lateral sclerosis (ALS). The agreement stipulates that Alchemab will oversee the initial Phase I clinical trials of the drug. Following the Phase I trials, Lilly will take over responsibility for the continued development and eventual commercialization of ATLX-1282. Under the terms of the deal, Alchemab will manage the early clinical testing of ATLX-1282, a novel platform, in patients with ALS. Subsequently, Eli Lilly and Company will handle later-stage development activities, including further clinical trials and, if successful, the process of bringing the drug to market. The companies have not disclosed further details about the parameters of the arrangement.

Newsflash | Powered by GeneOnline AI
Date: May 6, 2025

Author

Mark Chiang